Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25

14 May 2025 CW Team

The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

Infrastructure Transport

16 Sep 2025

Metro Line 2B Phase 1 to Boost Realty in Mumbai’s Eastern Suburbs

Mumbai’s real estate sector is set for a major boost as Phase 1 of Metro Line 2B, between Mandale and Diamond Garden, nears completion. The Mumbai Metropolitan Region Development Authority (MMRDA) has confirmed that mandatory rectifications are done, and inspections by the Commissioner of Metro Railway Safety (CMRS) have been carried out. The 5.39-km stretch with five stations forms part of the larger DN Nagar–Mandale corridor, designed to ease congestion and improve east–west connectivity. Passenger operations are expected by December 2025, with the full line slated for 2027. ..

Resources

16 Sep 2025

WattPower wins Best Inverter award at Global Solar Expo 2025

WattPower, a leading renewable energy solutions provider, has won the award for “Best Inverter in the Utility Segment” at the Global Solar Expo 2025. The recognition underscores the company’s commitment to delivering reliable, high-performance and future-ready solar solutions for large-scale projects. At the forefront of utility-scale solar, WattPower manufactures advanced string inverters that directly feed power into the Indian grid. With robust technology, high-quality components and comprehensive product lifecycle support, its solutions stand among the most sophisticated in the ..

Real Estate

16 Sep 2025

Awfis delivers 67,000 sq. ft. innovation hub for eBay in Bengaluru

Awfis Space Solutions, India’s largest flexible workspace provider and the first publicly listed workspace solutions platform, has partnered with eBay to establish a 67,000 sq. ft. innovation hub at Embassy Tech Village, Bengaluru. The mandate covers design, build and management of the new office, which will act as a strategic hub supporting diverse functions and accelerating eBay’s AI-first commerce strategy. The centre will focus on artificial intelligence, engineering, product development and applied research, strengthening eBay’s growth in India. Embassy Tech Village, North Beng..